Study of GZR18 in people with and without kidney problems
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests how a new drug called GZR18 (given as an injection) affects the body in people with different levels of kidney function. It aims to find the right dose and check for side effects, which could help guide treatment for people with kidney issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You weigh at least 110 pounds (50 kg) and have a BMI between 20 and 40
- You have either normal kidney function or mild, moderate, or severe kidney impairment
- You are not allergic to GLP-1 drugs (like Ozempic) or any ingredient in GZR18
- You do not have a history of pancreatitis, liver disease, or gallbladder problems
- You have not had a kidney transplant or need dialysis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called GZR18 to see how it works in people with different levels of liver function. It aims to help find the right dose and check safety.
This trial tests how a new injectable drug, GZR18, affects how fast your stomach empties and how it interacts with other medicines. It is for obese Chinese adults who want to join a research study.
This study tests a new injectable medicine for weight management in adults who are overweight. It aims to see how the medicine works in the body and how it affects weight.
This study is for people who finished a previous weight loss trial and want to continue treatment with an injectable medication GZR18. It tests how well the medicine works over a longer period.
This trial is testing an investigational medication (GZR18) to help people with obesity and obstructive sleep apnea (a condition where breathing stops during sleep) lose weight. It is given alongside the usual positive airway pressure (PAP) therapy, which helps keep the airway open during sleep. The goal is to see if the drug can improve weight and possibly sleep apnea symptoms.
This study tests an investigational injection called UBT251 for people with chronic kidney disease who are overweight. It aims to see if it can reduce protein in the urine and help protect kidney function.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.